HC Wainwright Has Negative Estimate for Evotec Q3 Earnings

Evotec AG (NASDAQ:EVO) – Investment analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Evotec in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.14) per share for the quarter, down from their prior estimate of ($0.04). HC Wainwright currently has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.83) EPS, FY2029 earnings at $0.21 EPS and FY2030 earnings at $0.28 EPS.

Other equities research analysts have also recently issued reports about the company. Berenberg Bank cut Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Evotec presently has an average rating of “Hold” and a consensus price target of $3.00.

Evotec Price Performance

Shares of EVO stock opened at $1.96 on Tuesday. The business has a 50 day moving average of $2.36 and a two-hundred day moving average of $2.79. Evotec has a 52 week low of $1.90 and a 52 week high of $4.27. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33.

Hedge Funds Weigh In On Evotec

A number of large investors have recently made changes to their positions in the business. Apollon Wealth Management LLC purchased a new stake in Evotec in the 1st quarter worth approximately $28,000. Marshall Wace LLP purchased a new stake in shares of Evotec during the fourth quarter worth $40,000. SmartHarvest Portfolios LLC acquired a new stake in Evotec during the first quarter valued at $44,000. BNP Paribas Financial Markets lifted its holdings in shares of Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares during the last quarter. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.